Summary of capabilities

Gosselies, Belgium

Viral vector development and analytical facilities

Overview:

Thermo Fisher Scientific's Gosselies facility, located in the heart of Belgium's largest biotech hub, is dedicated to the development of viral vectors, (process & analytical), for clinical applications. The facility has 380 square meters of classified cGMP space and 700 square meters of R&D space staffed by experts in the development of viral vectors, viruses, vaccines, and other therapies. The facility ensures a lean and efficient transfer from viral vector development to cGMP manufacturing. For information on our viral vector manufacturing services, click here to learn more about Seneffe.

Facility facts		Specialized capabilities
Capacity:	700 m2 (~ 7,500 sq. ft.) R&D space	• Experience in viral vector and virus development for cell & gene therapies, vaccine applications and other therapies. • Process & analytical development • Broad array of suspension and adherent process • Small to Mid-scale: up to 200L
Regulatory approval:	AFMPS, Belgium - Agence Fédérale des Médicaments et Produits de Santé	
Contact info:	16 rue Clément Ader, 6041 Gosselies, Belgium Tel: +32 71 347900	

Viral vector services capabilities detailed overview (Gosselies)

Facility Offering	Specifications	
Process Development (Gosselies)	• Upstream DOE studies in ambr 250 • 200L pilot bioreactor and Cell Stack 10/ Hyperstack36 adherent process – preclinical production and scale-up • Clarification optimization • Depth and other filtration methods • TFF concentration and buffer exchange	• Varied Chromatography modalities/resins: Affinity, SEC, IEX, HIC, etc. • Viral inactivation/clearance support • Centrifugal separations • Scale down process and Process Characterization
Process Characterization (Gosselies)	• Process Scale down, process design and process characterization	
Analytical Development (Gosselies)	• Assay establishment, customization and/or development • Activity, purity, product quality and yield (DOE) • Qualification & validation of methods	• DOE and Pre-clinical material testing • Transfer to QC for testing

Summary of capabilities

Flexible equipment options to scale manufacturing processes (Gosselies & Seneffe):

Platform	PD / Phase I–II	Ph I-III / PPQ / commercial
Adherent HEK293/Vero/others	ICellis Nano / ICellis 500 24 CS10 15 HS36	ICellis 500 24 CS10 15 HS36
Suspension HEK293	From 50L to 200L	From 50L to 200L
Suspension Sf9 / Baculovirus	From 50L to 200L	From 50L to 200L
Suspension other	From 50L to 200L	From 50L to 200L
Perfusion	From 50L to 200L	From 50L to 200L
Drug product		
Fill and finish	Up to 10,000 vials	

Production platforms and processes:

ADENOVIRAL

Adherent + Suspension
Mammalian cells infection

ADENO-ASSOCIATED VIRUS (AAV)

Producer cell line + Adv	Adherent + Suspension	Adherent + Suspension
Mammalian cells infection	Mammalian cells transient transfection	Insect cells – infection

HERPESVIRAL

Adherent + Suspension
Mammalian cells infection

LENTIVIRAL

Adherent + Suspension
Mammalian cells transient transfection

RETROVIRAL (RV)

Adherent + Suspension
Mammalian cells transient transfection

HERPESVIRAL (HSV)

Adherent + Suspension
Mammalian cells transient transfection

MODIFIED VACCINIA ANKARA MVA

Suspension
Infection + avian cell time

VESICULAR STOMATITIS VIRUS (VSV)

Adherent
Infection + Mammalian cells transient

VIRUS-LIKE PARTICLES (VLP)

Suspension
Insect cell + Mammalian infection

In addition, our team is experienced in supporting a variety of other viral platforms and other related products like VSV, RSV, Exosomes and more
For detailed capabilities and capacity information, please contact us

From molecule to medicine: An integrated partner for every step in your drug development journey.

Thermo Fisher Scientific provides industry-leading pharma services for drug development, clinical trial logistics, and commercial manufacturing through our Patheon™ brand. We partner with customers in the pharmaceutical, biotech, and life sciences industries as their trusted CDMO to deliver medicine to patients faster. With more than 60 facilities around the world, we provide end-to-end pharma services across all phases of development and commercial manufacturing, including API, oral solid dose, biologics, cell therapy, mRNA, viral vectors, formulation, clinical trial solutions, logistics services and packaging. We couple our scientific and technical excellence in these areas with a strategic partnership to provide customers of all sizes access to a global network of facilities and dedicated experts across the Americas, Europe, Asia, and Australia. Through our integrated service offerings, we provide tailored solutions to fit your unique drug development journey, accelerating your time to market.

Discover the power of partnership and our global network.

+1 919 226 3200 • thermofisher.com/patheon • pharmaservices@thermofisher.com